SIRT3 and neoplasm: In parallel, SIRT3 enhances OXPHOS efficiency via ETC assembly optimization in neoplasms, unveiling potential therapeutic vulnerabilities in OXPHOS-dependent malignancies such as pancreatic adenocarcinoma and BRAF-mutated melanomas258-261.